Search Medical Condition
Please enter condition
Please choose location from dropdown

Xiangya, China Clinical Trials

A listing of Xiangya, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (216) clinical trials

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events

Phase

0.14 miles

Learn More »

A Phase IV Study in Drug-Naive Patients With T2DM in China

Study design This is a 24-week, multicenter, randomized, open-label, parallel-group, active controlled Phase IV study The open-label study design rather than double-blind is considered due to the difficulty of placebo supply. The primary efficacy endpoint will be blinded to both patients and investigators, so the measurements as well as the ...

Phase

0.7 miles

Learn More »

Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants

The purpose of the study (retrospective and prospective) is to describe participant and disease characteristics and treatment pattern of Bortezomib treated mantle cell lymphoma (MCL) participants in China.

Phase N/A

0.7 miles

Learn More »

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin

Phase

0.7 miles

Learn More »

Efficacy Safety and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

This randomized, multicenter, open-label, Phase 3 study is designed to investigate the efficacy, safety, and pharmacokinetics of emicizumab in participants with hemophilia A regardless of factor VIII (FVIII) inhibitor status. Participants who received episodic therapy with FVIII or bypassing agents prior to study entry and experienced at least 5 bleeds ...

Phase

0.7 miles

Learn More »

A Study of Atezolizumab (Anti Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Phase

0.7 miles

Learn More »

Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One in Chinese Patients With Symptomatic Osteoarthritis of the Knee

The duration of the study will be 29 weeks at maximum. The screening and wash-out period may last for up to 14 days, depending on the half-life of the medications followed by an 8-day baseline period including the Treatment Day. Overall, there will be up to 21 days between signing ...

Phase

0.7 miles

Learn More »

Study on Efficacy and Safety of CaReSR-1S to Repair Cartilage Defects of the Knee

CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I. It is indicated for the defect filling of focal, full layer and clearly defined knee and ankle cartilage defects of longest diameter 1.1-2.2cm. The fixation of CaReSR-1S is made for all ...

Phase N/A

0.7 miles

Learn More »

Aromasin Non-Interventional Study Of Early Invasive Breast Cancer Patients In China

This is non-interventional study and single arm study. N/A

Phase

0.7 miles

Learn More »

The Mechanism of Modified Utral-long Protocol in Improving Endometrial Receptivity in Patients With PCOS and IR

The endometrial biopsy was performed in the previous cycle of the protocol. According to the expression of NF-B in the endometrium random group. The difference of NF - B expression in patients with different protocol were compared.

Phase N/A

0.7 miles

Learn More »